Question to the Department for Business, Energy and Industrial Strategy:

To ask Her Majesty's Government, further to the statement by the Secretary of State for Health and Social Care on 8 September (HC Deb, cols 517-519), what is the nature of the vaccines which form the basis of the agreements in place with six separate vaccine developers; and who are the developers.

The UK has secured access to 6 different candidates, across 4 different vaccine types, reflecting the government’s strategy to ensure the UK has a supply of vaccines should any of these prove safe and effective:

• Adenoviral vaccines (University of Oxford/AstraZeneca, Janssen);
• mRNA vaccines (BioNTech/Pfizer);
• Inactivated whole virus vaccines (Valneva);
• Protein adjuvant vaccines (GlaxoSmithKline/Sanofi, Novavax).